Celgene and Exscientia sign AI drug discovery deal in oncology and autoimmunity

This deal extends Exscientia’s list of partnerships with pharma and biotech companies, with existing collaborations involving Roche, GSK, Sanofi and Evotec.

Biogen and Eisai pull plug on Alzheimer’s drug

In January, another amyloid-targeting candidate, Roche's crenezumab, also failed in phase 3 trials..

Where next in Alzheimer’s disease R&D?

AC Immune and Roche factored these lessons into the development of crenezumab. ... Since 2012, AC Immune has partnered tau assets with Roche’s Genentech, Johnson &Johnson and Eli Lilly.

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase. Pfizer has stopped short of joining 2019's gene therapy buying spree, instead acquiring a 15% of Vivet Therapeutics, and securing an ... Recent weeks has seen some major M&A deals in the gene therapy

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]